Regulation of ubiquitin-proteasome and autophagy pathways after acute LPS and epoxomicin administration in mice

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Jamart, Cécile ^a   Gomes, Aldrin V ^b   Dewey, Shannamar ^b   Deldicque, Louise ^c   Raymackers, Jean Marc ^a   Francaux, Marc ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Endotoxemia; LC3; MAFbx; MuRF1; Proteasome inhibitors

Indexed keywords

ATROGIN 1; EPOXOMICIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; UBIQUITIN; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROCNEMIUS MUSCLE; LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEPSIS; SIGNAL TRANSDUCTION; STEADY STATE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; PHYSIOLOGY; RANDOMIZATION; TOXICITY;

ANIMALS; AUTOPHAGY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84901977836     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-166     Document Type: Article

References (55)

1. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Evans WJ, Am J Clin Nutr 2010 91 1123S 1127S 10.3945/ajcn.2010.28608A 20164314
2. Protein metabolism in different types of skeletal muscle during early and late sepsis in rats. Hasselgren PO, Talamini M, James JH, Fischer JE, Arch Surg 1986 121 918 923 10.1001/archsurg.1986.01400080064011 3729710 (Pubitemid 16039339)
3. Targeting the ubiquitin proteasome pathway for the treatment of septic shock in patients. Brun J, Gray DA, Crit Care 2009 13 311 10.1186/cc7946 19691815
4. The immunopathogenesis of sepsis. Cohen J, Nature 2002 420 885 891 10.1038/nature01326 12490963 (Pubitemid 36019643)
5. Animal models of sepsis and sepsis-induced kidney injury. Doi K, Leelahavanichkul A, Yuen PS, Star RA, J Clin Invest 2009 119 2868 2878 10.1172/JCI39421 19805915
6. Skeletal muscle protein balance in mTOR heterozygous mice in response to inflammation and leucine. Lang CH, Frost RA, Bronson SK, Lynch CJ, Vary TC, Am J Physiol Endocrinol Metab 2010 298 1283 E1294 10.1152/ajpendo.00676.2009 20388826
7. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. Dehoux MJ, van Beneden RP, Fernandez-Celemin L, Lause PL, Thissen JP, FEBS Lett 2003 544 214 217 10.1016/S0014-5793(03)00505-2 12782319 (Pubitemid 36628065)
8. Red blood cells contain a pathway for the degradation of oxidant-damaged hemoglobin that does not require ATP or ubiquitin. Fagan JM, Waxman L, Goldberg AL, J Biol Chem 1986 261 5705 5713 3009430 (Pubitemid 17207396)
9. Proteins damaged by oxygen radicals are rapidly degraded in extracts of red blood cells. Davies KJ, Goldberg AL, J Biol Chem 1987 262 8227 8234 3597373
10. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Asher G, Bercovich Z, Tsvetkov P, Shaul Y, Kahana C, Mol Cell 2005 17 645 655 10.1016/j.molcel.2005.01.020 15749015 (Pubitemid 40320915)
11. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Asher G, Tsvetkov P, Kahana C, Shaul Y, Genes Dev 2005 19 316 321 10.1101/gad.319905 15687255 (Pubitemid 40189294)
12. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Kisselev AF, Akopian TN, Castillo V, Goldberg AL, Mol Cell 1999 4 395 402 10.1016/S1097-2765(00)80341-X 10518220 (Pubitemid 29499792)
13. Modulation of inflammatory response in sepsis by proteasome inhibition. Safranek R, Ishibashi N, Oka Y, Ozasa H, Shirouzu K, Holecek M, Int J Exp Pathol 2006 87 369 372 10.1111/j.1365-2613.2006.00490.x 16965564 (Pubitemid 44370916)
14. A combination of proteasome inhibitors and antibiotics prevents lethality in a septic shock model. Reis J, Tan X, Yang R, Rockwell CE, Papasian CJ, Vogel SN, Morrison DC, Qureshi AA, Qureshi N, Innate Immun 2008 14 319 329 10.1177/1753425908096855 18809656
15. Proteasome inhibitors: from research tools to drug candidates. Kisselev AF, Goldberg AL, Chem Biol 2001 8 739 758 10.1016/S1074-5521(01)00056-4 11514224 (Pubitemid 32752454)
16. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM, Proc Natl Acad Sci U S A 1999 96 10403 10408 10.1073/pnas.96.18.10403 10468620 (Pubitemid 29422570)
17. Effects of beta-hydroxy-beta-methylbutyrate treatment in different types of skeletal muscle of intact and septic rats. Kovarik M, Muthny T, Sispera L, Holecek M, J Physiol Biochem 2010 66 311 319 10.1007/s13105-010-0037-3 20725872
18. Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction. Supinski GS, Vanags J, Callahan LA, Am J Physiol Lung Cell Mol Physiol 2009 296 994 L1001 10.1152/ajplung.90404.2008 19376888
19. Protein metabolism in leg muscle following an endotoxin injection in healthy volunteers. Vesali RF, Cibicek N, Jakobsson T, Klaude M, Wernerman J, Rooyackers O, Clin Sci (Lond) 2010 118 421 427
20. The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle. Kovarik M, Muthny T, Sispera L, Holecek M, J Physiol Biochem 2012 68 385 395 10.1007/s13105-012-0150-6 22311459
21. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. Doyle A, Zhang G, Abdel Fattah EA, Eissa NT, Li YP, FASEB J: Offic Publ Fed Am Soc Exp Biol 2011 25 99 110
22. Autophagy and skeletal muscles in sepsis. Mofarrahi M, Sigala I, Guo Y, Godin R, Davis EC, Petrof B, Sandri M, Burelle Y, Hussain SN, PLoS One 2012 7 47265 10.1371/journal.pone.0047265 23056618
23. Role of IGF-I and the TNFalpha/NF-kappaB pathway in the induction of muscle atrogenes by acute inflammation. Schakman O, Dehoux M, Bouchuari S, Delaere S, Lause P, Decroly N, Shoelson SE, Thissen JP, Am J Physiol Endocrinol Metab 2012 303 729 E739 10.1152/ajpendo.00060.2012 22739109
24. Cachexia: a new definition. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD, Clin Nutr 2008 27 793 799 10.1016/j.clnu.2008.06.013 18718696
25. Identification of ubiquitin ligases required for skeletal muscle atrophy. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ, Science 2001 294 1704 1708 10.1126/science.1065874 11679633 (Pubitemid 33104839)
26. Stain-Free total protein staining is a superior loading control to beta-actin for Western blots. Gilda JE, Gomes AV, Anal Biochem 2013 440 186 188 10.1016/j.ab.2013.05.027 23747530
27. Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. Gomes AV, Waddell DS, Siu R, Stein M, Dewey S, Furlow JD, Bodine SC, FASEB J: Offic Publ Fed Am Soc Exp Biol 2012 26 2986 2999
28. Crude and purified proteasome activity assays are affected by type of microplate. Cui Z, Gilda JE, Gomes AV, Anal Biochem 2014 446 44 52 24141075
29. Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, Stefani E, Ping P, Mol Cell Proteomics 2009 8 302 315 18931337
30. Mapping the murine cardiac 26S proteasome complexes. Gomes AV, Zong C, Edmondson RD, Li X, Stefani E, Zhang J, Jones RC, Thyparambil S, Wang GW, Qiao X, Bardag-Gorce F, Ping P, Circ Res 2006 99 362 371 10.1161/01.RES.0000237386. 98506.f7 16857966 (Pubitemid 44253692)
31. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F, Genome Biol 2002 3 ESEARCH0034 12184808
32. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ, Mol Cell 2004 14 395 403 10.1016/S1097-2765(04)00211-4 15125842 (Pubitemid 38591410)
33. Signaling in muscle atrophy and hypertrophy. Sandri M, Physiology (Bethesda) 2008 23 160 170 10.1152/physiol.00041.2007 18556469
34. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B, Science 1998 282 2085 2088 9851930 (Pubitemid 29001265)
35. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, Defronzo RA, Coletta DK, Sriwijitkamol A, Musi N, Diabetes 2008 57 2595 2602 10.2337/db08-0038 18633101
36. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE, Cell 2004 119 285 298 10.1016/j.cell.2004.09. 027 15479644 (Pubitemid 39360909)
37. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB, FASEB J: Offic Publ Fed Am Soc Exp Biol 2005 19 362 370 (Pubitemid 40316524)
38. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, Azuma J, Cardiovasc Res 2008 79 89 96 10.1093/cvr/cvn076 18346979 (Pubitemid 351881941)
39. Curcumin prevents lipopolysaccharide-induced atrogin-1/MAFbx upregulation and muscle mass loss. Jin B, Li YP, J Cell Biochem 2007 100 960 969 10.1002/jcb.21060 17131360
40. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Rodgers KJ, Dean RT, Int J Biochem Cell Biol 2003 35 716 727 10.1016/S1357-2725(02)00391-6 12672463 (Pubitemid 36369519)
41. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Ishii T, Sakurai T, Usami H, Uchida K, Biochemistry 2005 44 13893 13901 10.1021/bi051336u 16229478 (Pubitemid 41507469)
42. Autophagy: assays and artifacts. Barth S, Glick D, Macleod KF, J Pathol 2010 221 117 124 10.1002/path.2694 20225337
43. Autophagy: from phenomenology to molecular understanding in less than a decade. Klionsky DJ, Nat Rev Mol Cell Biol 2007 8 931 937 10.1038/nrm2245 17712358 (Pubitemid 47622558)
44. Monitoring autophagic degradation of p62/SQSTM1. Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T, Methods Enzymol 2009 452 181 197 19200883
45. How to interpret LC3 immunoblotting. Mizushima N, Yoshimori T, Autophagy 2007 3 542 545 17611390 (Pubitemid 350060049)
46. Pregnancy is associated with decreased cardiac proteasome activity and oxidative stress in mice. Iorga A, Dewey S, Partow-Navid R, Gomes AV, Eghbali M, PLoS One 2012 7 48601 10.1371/journal.pone.0048601 23166589
47. Endotoxemia impairs heart mitochondrial function by decreasing electron transfer, ATP synthesis and ATP content without affecting membrane potential. Vanasco V, Magnani ND, Cimolai MC, Valdez LB, Evelson P, Boveris A, Alvarez S, J Bioenerg Biomembr 2012 44 243 252 10.1007/s10863-012-9426-3 22426814
48. Proteasomal AAA-ATPases: Structure and function. Bar-Nun S, Glickman MH, Biochim Biophys Acta 1823 2012 67 82
49. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. Tawa NE Jr, Odessey R, Goldberg AL, J Clin Invest 1997 100 197 203 10.1172/JCI119513 9202072 (Pubitemid 27311258)
50. The route of absorption of intraperitoneally administered compounds. Lukas G, Brindle SD, Greengard P, J Pharmacol Exp Ther 1971 178 562 564 5571904
51. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL, Lancet Oncol 2011 12 431 440 10.1016/S1470-2045(11)70081-X 21507715
52. Prevention of muscle disuse atrophy by MG132 proteasome inhibitor. Jamart C, Raymackers JM, Li An G, Deldicque L, Francaux M, Muscle Nerve 2011 43 708 716 10.1002/mus.21949 21462205
53. The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. Caron AZ, Haroun S, Leblanc E, Trensz F, Guindi C, Amrani A, Grenier G, BMC Musculoskelet Disord 2011 12 185 10.1186/1471-2474-12- 185 21843349
54. Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Zhao J, Brault JJ, Schild A, Goldberg AL, Autophagy 2008 4 378 380 18227643 (Pubitemid 351458106)
55. Exercise training has beneficial anti-atrophy effects by inhibiting oxidative stress-induced MuRF1 upregulation in rats with diabetes. Chen GQ, Mou CY, Yang YQ, Wang S, Zhao ZW, Life Sci 2011 89 44 49 10.1016/j.lfs.2011.04.018 21620866